Feb. 20 at 8:07 PM
$AIDX IPO'd yesterday (Feb 19). Currently down ~44% on its second day of trading.
Two objective factors to consider:
Sector Context: Operates in the liquid biopsy/early cancer detection space. The entire sector is under pressure today following the
$GRAL trial results (-50%).
Technicals: The stock is in a price discovery phase. There are zero established support levels or moving averages.
Next scheduled event: Investor webinar on Feb 26.
Trading a Day-2 IPO without a defined stop loss is strictly a gamble. Plan accordingly.